Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the Craig-Hallum Alpha Select Conference in November 2026.
Stocks · News reference
TD Cowen Maintains Buy on Exagen, Raises Price Target to $11
TD Cowen analyst Dan Bergstrom maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $10 to $11.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Exagen Inc. to Announce Third Quarter 2026 Financial Results on November 10, 2026
Exagen Inc. has scheduled the release of its financial results for the third quarter ended September 30, 2026, for the morning of November 10, 2026.
Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11
Full Transcript: Exagen Q2 2026 Earnings Call
On Tuesday, Exagen (NASDAQ:XGN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and
TD Cowen Maintains Buy on Exagen, Raises Price Target to $10
TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $10.
B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $12.